Literature DB >> 24825862

Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.

Fumio Nakahara1, Jiro Kitaura1, Tomoyuki Uchida1, Chiemi Nishida2, Katsuhiro Togami1, Daichi Inoue1, Toshihiro Matsukawa1, Yuki Kagiyama1, Yutaka Enomoto1, Kimihito C Kawabata1, Lai Chen-Yi3, Yukiko Komeno1, Kumi Izawa1, Toshihiko Oki4, Genta Nagae5, Yuka Harada6, Hironori Harada7, Makoto Otsu3, Hiroyuki Aburatani5, Beate Heissig8, Koichi Hattori2, Toshio Kitamura9.   

Abstract

High levels of HES1 expression are frequently found in BCR-ABL(+) chronic myelogenous leukemia in blast crisis (CML-BC). In mouse bone marrow transplantation (BMT) models, co-expression of BCR-ABL and Hes1 induces CML-BC-like disease; however, the underlying mechanism remained elusive. Here, based on gene expression analysis, we show that MMP-9 is upregulated by Hes1 in common myeloid progenitors (CMPs). Analysis of promoter activity demonstrated that Hes1 upregulated MMP-9 by activating NF-κB. Analysis of 20 samples from CML-BC patients showed that MMP-9 was highly expressed in three, with two exhibiting high levels of HES1 expression. Interestingly, MMP-9 deficiency impaired the cobblestone area-forming ability of CMPs expressing BCR-ABL and Hes1 that were in conjunction with a stromal cell layer. In addition, CMPs expressing BCR-ABL and Hes1 secreted MMP-9, promoting the release of soluble Kit-ligand (sKitL) from stromal cells, thereby enhancing proliferation of the leukemic cells. In accordance, mice transplanted with CMPs expressing BCR-ABL and Hes1 exhibited high levels of sKitL as well as MMP-9 in the serum. Importantly, MMP-9 deficiency impaired the development of CML-BC-like disease induced by BCR-ABL and Hes1 in mouse BMT models. The present results suggest that Hes1 promotes the development of CML-BC, partly through MMP-9 upregulation in leukemic cells.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24825862     DOI: 10.1182/blood-2013-01-476747

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  MicroRNA-144 targets APP to regulate AML1/ETO+ leukemia cell migration via the p-ERK/c-Myc/MMP-2 pathway.

Authors:  Ling Jiang; Wei Meng; Guopan Yu; Changxin Yin; Zhixiang Wang; Libin Liao; Fanyi Meng
Journal:  Oncol Lett       Date:  2019-06-14       Impact factor: 2.967

2.  Aberrant activation of CaMKIIγ accelerates chronic myeloid leukemia blast crisis.

Authors:  Y Gu; W Zheng; J Zhang; X Gan; X Ma; Z Meng; T Chen; X Lu; Z Wu; W Huang; R Xu
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

3.  Protease-activated receptor-1 inhibits proliferation but enhances leukemia stem cell activity in acute myeloid leukemia.

Authors:  S Goyama; M Shrestha; J Schibler; L Rosenfeldt; W Miller; E O'Brien; B Mizukawa; T Kitamura; J S Palumbo; J C Mulloy
Journal:  Oncogene       Date:  2016-11-07       Impact factor: 9.867

4.  Hes1 Controls Proliferation and Apoptosis in Chronic Lymphoblastic Leukemia Cells by Modulating PTEN Expression.

Authors:  Qikai Zhang; Zongsi Zhu; Jiaqiang Guan; Yingying Hu; Wenjin Zhou; Wanchun Ye; Bijing Lin; Shanshan Weng; Yuemiao Chen; Cuiping Zheng
Journal:  Mol Biotechnol       Date:  2022-06-15       Impact factor: 2.860

5.  miR-381 Regulates Neural Stem Cell Proliferation and Differentiation via Regulating Hes1 Expression.

Authors:  Xiaodong Shi; Chunhua Yan; Baoquan Liu; Chunxiao Yang; Xuedan Nie; Xiaokun Wang; Jiaolin Zheng; Yue Wang; Yulan Zhu
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

6.  Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.

Authors:  Abdullah Aljedai; Anne-Marie Buckle; Prashant Hiwarkar; Farhatullah Syed
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

7.  The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer.

Authors:  Yinfang Wu; Lijie Gong; Ji Xu; Yiping Mou; Xiaowu Xu; Zhenyuan Qian
Journal:  Onco Targets Ther       Date:  2017-12-08       Impact factor: 4.147

8.  Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature.

Authors:  Rohit Gulati; Yaser Alkhatib; Vijayalakshmi Donthireddy; Michelle Madden Felicella; Madhu P Menon; Kedar V Inamdar
Journal:  Case Rep Pathol       Date:  2015-12-24

9.  RNA-binding protein Musashi2 induced by RANKL is critical for osteoclast survival.

Authors:  T Fujiwara; J Zhou; S Ye; H Zhao
Journal:  Cell Death Dis       Date:  2016-07-21       Impact factor: 8.469

10.  Bioinformatics analysis and identification of hub genes and immune-related molecular mechanisms in chronic myeloid leukemia.

Authors:  Fangyi Yao; Cui Zhao; Fangmin Zhong; Tingyu Qin; Shuqi Li; Jing Liu; Bo Huang; Xiaozhong Wang
Journal:  PeerJ       Date:  2022-01-18       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.